Article written by Christine Clark Numerous clinical trials with ivermectin in covid-19 have shown consistent, large magnitude improvements in clinical outcomes that are little short of spectacular but… read more.
Our immune system’s capacity to mount a well-regulated defence against foreign substances, including toxins, weakens with age and makes vaccines less effective in people over age 65..
Article written by Christine Clark As the number of signatures on the Great Barrington Declaration nears half a million, support for the focused protection that it advocates appears… read more.
Article written by Christine Clark Flu vaccination is safe, effective and is offered free of charge to thirty million people in the UK this year in the country’s… read more.
Article written by Christine Clark Leading scientists propose a ‘more humane’ strategy for the management of the coronavirus pandemic.
Falls are the leading cause of fatal injuries in older adults, causing more than 800,000 hospitalizations and about 30,000 deaths in the U.S. every year. Some risk factors… read more.
A new study conducted by a team of researchers, found while social distancing is an effective preventative measure in the fight against COVID-19, there are significant variations being observed… read more.
One in four older Americans had a virtual medical visit in the first three months of the COVID-19 pandemic, most of them by video, a new telehealth poll finds.
Article written by Bruce Sylvester Glycated hemoglobin A1c (HbA1c) greater than 7% correlates with an increased risk of cardiovascular events in elderly patients..
Article written by Bruce Sylvester Elderly patients without atherosclerotic cardiovascular disease (ASCVD) who initiated statin therapy have achieved a 25% reduction in the risk of early death..
Moderna, Inc. announced the publication of an interim analysis of the open-label Phase 1 study of mRNA-1273, its vaccine candidate against COVID-19, in The New England Journal of… read more.
Idorsia Ltd announced positive top-line results of the second pivotal Phase III study investigating 10 and 25 mg doses of its dual orexin receptor antagonist, daridorexant , in… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
